1.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retro...
by Albain, Kathy S, Prof
The lancet oncology, 2010, Vol.11 (1), p.55-65
2.
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
by Albain, Kathy S, Prof
The Lancet (British edition), 2009, Vol.374 (9687), p.379-386
3.
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
by Albain, Kathy S, Prof
The Lancet (British edition), 2009, Vol.374 (9707), p.2055-2063
4.
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinica...
by Margolese, Richard G, Prof
The Lancet (British edition), 2015, Vol.387 (10021), p.849-856
5.
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a rand...
by Ganz, Patricia A, Prof
The Lancet (British edition), 2015, Vol.387 (10021), p.857-865
6.
Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Gl...
by Distelhorst, Sandra R, BA
The lancet oncology, 2015, Vol.16 (3), p.e137-e147
